

Viral Vectors *for* Vaccine Delivery

◆ Edited By
Vivek P. Chavda
Vasso Apostolopoulos

 Scrivener
Publishing

WILEY

Viral Vectors for Vaccine Delivery

Scrivener Publishing

100 Cummings Center, Suite 541J
Beverly, MA 01915-6106

Publishers at Scrivener

Martin Scrivener (martin@scrivenerpublishing.com)
Phillip Carmical (pcarmical@scrivenerpublishing.com)

Viral Vectors for Vaccine Delivery

Edited by

Vivek P. Chavda

*Dept. of Pharmaceutics and Pharmaceutical Technology,
L. M. College of Pharmacy, Ahmedabad, Gujarat, India*

and

Vasso Apostolopoulos

*School of Health and Biomedical Sciences, RMIT University, Melbourne,
Victoria, Australia*



WILEY

This edition first published 2025 by John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA and Scrivener Publishing LLC, 100 Cummings Center, Suite 541J, Beverly, MA 01915, USA

© 2025 Scrivener Publishing LLC

For more information about Scrivener publications please visit www.scrivenerpublishing.com.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

Wiley Global Headquarters

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Limit of Liability/Disclaimer of Warranty

While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read.

Library of Congress Cataloging-in-Publication Data

ISBN 978-1-394-27153-5

Front cover image courtesy of Adobe Firefly

Cover design by Russell Richardson

Set in size of 11pt and Minion Pro by Manila Typesetting Company, Makati, Philippines

Printed in the USA

10 9 8 7 6 5 4 3 2 1

Contents

Preface	xv
1 Introduction to Viral Vectors	1
<i>Anjali P. Bedse, Suchita P. Dhamane, Shilpa S. Raut, Komal P. Mahajan and Kajal P. Baviskar</i>	
1.1 Introduction	2
1.2 Baculovirus Vectors	3
1.3 Adenovirus Vectors	4
1.4 Poxvirus Vectors	6
1.5 Herpes Virus Vectors	8
1.6 Epstein-Barr Virus Vectors	9
1.7 Retrovirus Vectors	10
1.8 Lentivirus Vectors	11
1.9 Adeno-Associated Virus (AAV)	13
1.10 Applications of Viral Vectors	14
1.10.1 Viral Vectors for Vaccine Development	14
1.10.2 Gene Therapy: The Performance of Viral Vectors	15
1.10.3 Clinical Trials	15
1.11 Safety Issues of Viral Vector/Biosafety Challenges	16
1.12 Conclusion	18
References	19
2 Viral Vector Construction	25
<i>Suneetha Vuppu, Toshika Mishra, Shatakshi Mishra, Stany B. and Anushka Das</i>	
2.1 Introduction	26
2.2 Applications of Viral Vector	27
2.3 Viral Vectors	29
2.3.1 Adenoviruses	29
2.3.2 Retroviruses	35
2.3.3 Lentiviruses	36
2.3.4 Poxviruses	36

2.3.5	Adeno-Associated Viruses	37
2.3.6	Herpes Simplex Viruses	38
2.3.7	Alphaviruses	39
2.3.8	Flaviviruses	39
2.3.9	Rhabdoviruses	40
2.3.10	Newcastle Disease Virus	40
2.3.11	Coxsackieviruses	41
2.3.12	Measles Virus	41
2.4	Construction of Viral Vectors	42
2.5	Challenges	46
2.5.1	Immune Response	46
2.5.2	Specificity of the Transgene Delivery	47
2.5.3	Insertional Mutagenesis	48
2.6	Advancements in Technology of Viral Vector Construction	49
2.7	Conclusion and Future Prospects	51
	Acknowledgments	53
	References	53
3	The Role of Adjuvants in the Application of Viral Vector Vaccines	65
	<i>Vivek P. Chavda, Anjali P. Bedse and Shilpa S. Raut</i>	
3.1	Introduction	66
3.2	Viral Vector Vaccines: A Powerful Platform	67
3.3	Challenges Associated with Viral Vector Vaccines	69
3.3.1	Preexisting Immunity against the Viral Vector	69
3.3.2	Safety Concerns Related to Insertional Mutagenesis	70
3.3.3	Scalability and Manufacturing Challenges	72
3.4	The Role of Adjuvants in Overcoming Challenges	72
3.4.1	Mechanisms of Action of Adjuvants	72
3.4.2	Innate Immune Stimulation	73
3.4.3	Adaptive Immune Response Enhancement	73
3.4.4	Different Classes of Adjuvants Used with Viral Vector Vaccines	74
3.4.4.1	Classes of Adjuvants	74
3.4.5	Targeting CLR Pathway	75
3.4.6	Saponins	75
3.4.7	Cytokines and Chemokines	76
3.4.8	Case Studies of Specific Adjuvants Used with Viral Vector Vaccines	76
3.5	Optimizing Adjuvant Design for Viral Vector Vaccines	76
3.5.1	Importance of Adjuvant Selection and Formulation	76

3.5.2	Adjuvant Formulation Development	77
3.5.3	Adjuvant Formulations for the Development of New Vaccines	77
3.5.4	Strategies for Optimizing Adjuvant Design	78
3.5.4.1	Dose Sparing	78
3.5.4.2	Enabling a More Rapid Immune Response	78
3.5.4.3	Antibody Response Broadening	78
3.5.4.4	Antibody Response Magnitude and Functionality	79
3.5.5	Delivery Systems	79
3.5.5.1	Targeting Specific Immune Cell Populations	79
3.5.5.2	Combination Adjuvants	79
3.5.5.3	Challenges and Future Directions in Adjuvant Development for Viral Vector Vaccines	80
3.6	Conclusion	80
	References	81
4	Replication-Competent Viral Vectors for Vaccine Delivery	91
	<i>Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, Divya Teli, Amit Chaudhari and Shahnaz Alom</i>	
4.1	Introduction	92
4.2	Types of Replication-Competent Viral Vectors	93
4.2.1	Adenoviruses (AdVs)	93
4.2.2	Vesicular Stomatitis Viruses (VSVs)	93
4.2.3	Modified Vaccinia Ankara (MVA)	94
4.2.4	Measles Virus (MV)	94
4.2.5	Influenza Virus (IV)	95
4.3	Mechanisms of RCVV-Mediated Vaccination	97
4.4	Applications of Replication-Competent Viral Vectors	101
4.4.1	Prophylactic Vaccines	101
4.4.2	Therapeutic Vaccines	102
4.4.2.1	Vesicular Stomatitis Virus	102
4.4.2.2	Cytomegalovirus	103
4.4.2.3	Measles Virus	104
4.4.2.4	Adenoviral Vectors	104
4.4.2.5	Applications of Replication-Competent Viral Vectors against COVID-19	105
4.4.3	Cancer Immunotherapy	111
4.5	Conclusion	115
	References	116

5	Nonreplicating Viral Vectors for Vaccine Delivery	125
	<i>Pankti C. Balar and Vivek P. Chavda</i>	
5.1	Introduction	126
5.2	Nonreplicating Viral Vectors: Types and Characteristics	127
5.2.1	Adenoviral Vectors	127
5.2.2	Non-Adenoviral Vectors	128
5.2.3	Key Characteristics of Nonreplicating Vectors	129
5.2.3.1	Immunogenicity	129
5.2.3.2	Safety	130
5.2.3.3	Stability	131
5.2.3.4	Targeted Delivery	131
5.3	Engineering Nonreplicating Viral Vectors for Vaccine Design	132
5.3.1	Capsid Modification	132
5.3.2	Promoter Engineering	133
5.3.3	Transgene Optimization	134
5.3.4	Immune Evasion Strategies	134
5.4	Applications of Nonreplicating Viral Vectors in Vaccinology	136
5.5	Optimizing Nonreplicating Viral Vectors for Vaccine Delivery	138
5.5.1	Enhancing Transduction Efficiency	138
5.5.2	Reducing Immunogenicity and Toxicity	139
5.5.3	Improving Antigen Expression and Presentation	139
5.5.4	Addressing Preexisting Immunity	140
5.5.5	Targeting Vector Delivery to Secondary Lymphoid Organs	141
5.6	Challenges and Future Perspectives	141
5.7	Conclusion	143
	References	144
6	Genetically Modified Viral Vectors for Vaccine Delivery	149
	<i>Deepshi Arora, Yugam Taneja, Diksha Gulati, Manish Kumar, Anil Pareek and Rupesh K. Gautam</i>	
6.1	Introduction	150
6.2	Genetic Modification of Viral Vectors	153
6.3	Applications of Genetically Modified Viral Vectors	155
6.4	Administration of Vaccines	159
6.5	Immune Response and Protection	161
6.6	Case Studies	163
6.7	Challenges and Future Directions	165
6.8	Conclusion	168
	References	171

7	DNA- and RNA-Based Viral Vectors	179
	<i>Devesh U. Kapoor, Bhumi Bhatt, Dipansu Sahu, Rajiv R. Kakkar, Sonam M. Gandhi and Rupesh K. Gautam</i>	
7.1	Introduction to Viral Vectors	180
7.1.1	Definition and Overview	180
7.1.2	Importance in Vaccine Delivery and Vaccination	180
7.2	Basics of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) Viruses	180
7.2.1	Structure and Replication of DNA Viruses	181
7.2.2	Structure and Replication of RNA Viruses	181
7.2.3	Characteristics Relevant to Vector Development	182
7.2.3.1	Plasmids	182
7.2.3.2	Viral Vectors	183
7.2.3.3	Artificial Chromosomes	183
7.3	DNA-Based Viral Vectors	183
7.3.1	Adenoviral Vectors	183
7.3.1.1	Advantages and Limitations of Adenoviral Vectors	185
7.3.1.2	Adenoviral Vectors Applications in Vaccination	186
7.3.2	Lentiviral Vectors	187
7.3.2.1	Advantages and Limitations of Lentiviral Vectors	188
7.3.2.2	Lentiviral Vectors Applications in Vaccination	189
7.3.3	Adeno-Associated Viral Vectors	190
7.3.3.1	Advantages and Limitations of AAV	190
7.3.3.2	AAV Applications in Gene Therapy and Vaccination	191
7.3.4	Other DNA-Based Viral Vectors	193
7.3.4.1	Baculoviral Vectors	193
7.3.4.2	Herpes Simplex Virus Vectors	193
7.3.4.3	Poxviral Vectors	193
7.4	RNA-Based Viral Vectors	194
7.4.1	Retroviral Vectors	194
7.4.1.1	Advantages and Limitations	195
7.4.2	Lentiviral Vectors	196
7.4.2.1	Advantages and Limitations	197
7.4.3	Alphaviral Vectors	201
7.4.3.1	Advantages and Limitations	201

7.4.4	Other RNA-Based Viral Vectors	203
7.4.4.1	Sendai Virus Vectors	204
7.4.4.2	Vesicular Stomatitis Virus Vectors	205
7.5	Vector Engineering and Modifications	205
7.5.1	Enhancing Vector Safety	206
7.5.2	Improving Vector Targeting and Tropism	207
7.5.3	Regulatory Considerations and Quality Control	207
7.6	Preclinical and Clinical Applications	208
7.6.1	Gene Therapy Applications	209
7.6.1.1	Inherited Disorders	209
7.6.1.2	Neurological Disorders	210
7.6.2	Vaccination Applications	210
7.6.2.1	Viral Vector-Based Vaccines	210
7.6.2.2	Genetic Vaccines	212
7.7	Conclusion	212
	References	213
8	Manufacturing and Control of Viral-Vector Vaccines: Challenges	221
	<i>Vivek P. Chavda, Dixa A. Vaghela, Dhunusmita Barman, Arzoo Newar and Ahmed Nasima</i>	
8.1	Introduction	222
8.2	Fundamentals of Viral-Vectored Vaccine Manufacturing	223
8.2.1	Viral Vector Construction	223
8.2.2	Development of the Viral Vector in Bacteria Through Homologous Recombination	224
8.2.2.1	Production of the Viral Vector Using Cre/loxP Recombination System	224
8.2.3	Cell Line Development	224
8.2.3.1	Designer Cell Lines and Cell Line Immortalization	225
8.2.3.2	Development of Stable Cell Lines for Vaccine Constitutive Expression	226
8.2.4	Upstream Processing	226
8.2.4.1	Cultivation Process and Harvest Timing of the Virus	226
8.2.5	Downstream Processing	227
8.2.5.1	Purification of Viral Vectors	227
8.2.5.2	Purification of a Large Stock of Viral Vector	227
8.2.5.3	Purification of Viral Vectors Using CsCl Density Gradient Centrifugation	228

8.2.5.4	Stable Liquid Virus Formulation Development	228
8.3	Challenges in Manufacturing Viral-Vectored Vaccines	229
8.3.1	Scale-Up and Production Yield Challenges	229
8.3.2	Ensuring Genetic Stability and Vector Integrity	230
8.3.3	Manufacturing Consideration for Different Vector Types	234
8.4	Quality Control and Assurance in Vaccine Manufacturing	235
8.4.1	Regulatory Requirements and Quality Standards	236
8.4.2	Analytical Methods for Assessing Viral Vector Purity and Potency	237
8.4.3	Process Validation and Quality Assurance Strategies	238
8.4.3.1	Process Validation Using a Life Cycle Approach: From R&D to Clinical Trials to Commercial Scale Regulation	239
8.4.3.2	Validation Strategy Based on Risk: Quality Risk Management System	239
8.5	Technological Advances and Innovations in Manufacturing	239
8.5.1	Novel Manufacturing Platforms and Technologies	239
8.5.2	Automation and Process Optimization	243
8.6	Supply Chain and Distribution Challenges	244
8.7	Regulatory Hurdles and Compliances	246
8.7.1	Regulatory Approval Challenges	246
8.7.2	Compliances with Good Manufacturing Practices (GMP)	246
8.7.3	Strategies for Navigating Regulatory Pathways	247
8.8	Future Perspectives and Emerging Solutions	248
8.9	Conclusion	248
	References	249
9	Viral Vectors in Veterinary Vaccine Development	257
	<i>Anup Kumar, Pooja Pandita, Harsh Modi, Shahnaz Alom and Vivek P. Chavda</i>	
9.1	Introduction	258
9.2	Basics of Viral Vectors	259
9.2.1	Definition and Characteristics of Viral Vectors	259
9.2.2	Types of Viral Vectors Used in Veterinary Vaccines	260
9.2.3	Advantages and Limitations of Viral Vectors	261
9.3	Genetic Engineering of Viral Vectors	262
9.3.1	Design and Construction of Viral Vectors	262
9.3.1.1	Gene Insertion Techniques	262
9.3.1.2	Promoters and Enhancers	262

9.3.2	Safety Measures and Biosafety Considerations	263
9.3.3	Quality Control and Characterization	263
9.4	Delivery System for Viral Vector Vaccines	265
9.4.1	Application of Nanotechnology in Vaccine Delivery	265
9.4.2	Targeted Delivery Approaches: Viral Vectors as Nanocarriers for Targeted Mucosal and Systemic Vaccine Delivery System	267
9.4.3	Novel Delivery Platforms and Technologies	268
9.4.3.1	Transdermal Vaccine Delivery System	268
9.4.3.2	Microneedle Arrays Delivery System for Viral Vector Vaccine	269
9.4.3.3	Viral Vector for DNA Vaccine Delivery	270
9.4.3.4	Needle-Free Vaccination for Viral Vector Vaccine Delivery	271
9.4.3.5	Combination Vaccine Regimen for Viral Vector Vaccine Delivery	272
9.5	Routes of Administration for Viral Vector Vaccines	272
9.5.1	Parenteral Route of Administration	273
9.5.1.1	Intravenous Route	273
9.5.1.2	Intramuscular Route	273
9.5.1.3	Subcutaneous Route	274
9.5.1.4	Intradermal Route	274
9.5.2	Mucosal Route of Administration	274
9.5.2.1	Intranasal Route	275
9.5.2.2	Oral Route	276
9.6	Comparative Analysis of Different Administration Routes	276
9.6.1	Parenteral Vaccine Delivery System	276
9.6.2	Mucosal Vaccine Delivery System	277
9.6.3	Challenges of the Mucosal Delivery System	278
9.6.3.1	Advantages of the Oral Route	278
9.6.3.2	Challenges of Oral Route	279
9.6.3.3	Advantages of Intranasal Route	279
9.6.3.4	Challenges of Intranasal Route	279
9.7	Applications of Viral Vectors in Veterinary Vaccine Development	280
9.7.1	Live Attenuated Viral Vector Vaccines	280
9.7.2	Inactivated Viral Vector Vaccines	280
9.7.3	DNA-Based Viral Vector Vaccines	281
9.7.4	Subunit Viral Vector Vaccines	281
9.7.5	Recombinant Viral Vector Vaccines	282
9.7.6	Examples of Veterinary Vaccines Using Viral Vectors	282

9.8	Immunology and Immune Response	285
9.8.1	Mechanisms of Immune Response to Viral Vector Vaccines	285
9.8.2	Adjuvants and Immune Enhancement	286
9.8.3	Immune Memory and Longevity	287
9.9	Safety and Regulatory Considerations	291
9.9.1	Safety Assessment and Preclinical Studies	291
9.9.2	Regulatory Approval Process for Veterinary Viral Vector Vaccines	292
9.9.3	Post-Market Surveillance and Monitoring	293
9.10	Notable Examples of Viral Vector Vaccines in Veterinary Medicine and Their Impact on Animal Health and Agriculture	295
9.11	Challenges and Future Directions	297
9.12	Conclusion	299
	References	300
10	Advantages and Challenges of Viral Vector Vaccines	317
	<i>Shilpa Dawre, Mahendra Prajapati and Ganesh Shevalkar</i>	
10.1	Introduction	317
10.2	Types of Viral Vectors for Vaccine Development	319
10.2.1	Poxviruses Vectors	319
10.2.2	Adenovirus Vectors	322
10.2.3	Retrovirus Vectors	322
10.2.4	Lentivirus Vectors	323
10.2.5	Cytomegalovirus Vectors	323
10.2.6	Sendai Virus Vectors	323
10.2.7	Adeno-Associated Virus Vectors	324
10.3	Mechanism of Action of Viral Vectors	324
10.3.1	Self-Adjuvanting Nature of Viral Vector Vaccines	325
10.3.2	Enhanced Cytotoxic CD8 ⁺ T Lymphocyte Production	326
10.3.3	Conformational Antigen Expression on Host Cell Membranes Infected by a Vector	327
10.3.4	Sustained Supply of Significant Amounts of Antigen	327
10.4	Advantages of Viral Vector Vaccines	327
10.4.1	Safety	328
10.4.2	Stability	328
10.4.3	Immunogenicity	328
10.4.3.1	Humoral Immunity	329
10.4.3.2	Cell-Mediated Immunity	329

10.4.3.3	Mucosal Immunity	330
10.5	Challenges of Viral Vector Vaccine	331
10.5.1	Development of Immunity Against Viral Vectors	331
10.5.2	Adverse Events	331
10.5.3	Scale-Up Hurdles in Viral Vector Production	332
10.5.3.1	Complexity and Variability of the Process	332
10.5.3.2	Low Yield and High Cost	333
10.5.3.3	Regulatory and Quality Control Challenges	333
10.5.3.4	Restrictions of Frequent Culture Systems	334
10.5.3.5	Formulation and Storage of Viral Vector Products	334
10.5.3.6	Requirement of High-Cost Technologies	335
10.5.3.7	Handling and Shipment	335
10.6	Conclusion	336
	References	336
11	Commercially Available Viral Vectors and Vaccines	341
	<i>Vasso Apostolopoulos, Pankti C. Balar, Arun Kumar Singh and Vivek P. Chavda</i>	
11.1	Introduction	342
11.2	Viral Vector-Based Vaccines, Licensed for Humans	342
11.2.1	Adenovirus Vector Vaccines	342
11.2.2	Vesicular Stomatitis Virus Vector Vaccines	346
11.2.3	Flavivirus Vector Vaccines	347
11.2.4	Combination Virus Vectors: Ad5/Ad26	348
11.2.5	Combination Virus Vectors: Ad5/VSV	348
11.2.6	Measles Virus Vector Vaccines	349
11.2.7	Poxvirus Vector Vaccines	349
11.3	Conclusion	350
	References	350
12	Emerging Viral-Vector Technologies: Future Potential	357
	<i>Vasso Apostolopoulos, Pankti C. Balar and Vivek P. Chavda</i>	
12.1	Introduction	358
12.2	New Emerging Viral Vectors for Vaccines	358
12.3	Viral Vector Vaccines: What is Good and What is Not So Good	360
12.4	Conclusion	361
	References	361
	Index	365

Preface

The development of vaccines has been a cornerstone of public health, preventing countless diseases and saving millions of lives. However, traditional vaccine approaches often face limitations, such as the need for multiple doses, the potential for adverse reactions, and the inability to induce long-lasting immunity against complex pathogens. In recent decades, viral vectors have emerged as a promising alternative, revolutionizing the field of vaccine development.

This book provides a comprehensive overview of viral vectors and their applications in vaccine delivery. Its chapters explore various aspects of viral vector technology, from the basic principles of viral vector construction to the latest advancements in gene editing and manufacturing.

To begin, the book introduces the concept of viral vectors and their advantages over traditional vaccine platforms. Subsequent chapters delve into the intricacies of viral vector construction, including the selection of appropriate viral backbones, the insertion of foreign genes, and the optimization of vector design for maximum immunogenicity. The role of adjuvants in enhancing the efficacy of viral vector vaccines is also discussed, highlighting their importance in boosting immune responses and improving vaccine potency.

The next section explores the different types of viral vectors used for vaccine delivery, including replication-competent and non-replicating vectors. Replication-competent vectors mimic natural infections, inducing a robust immune response, while non-replicating vectors are safer but may require multiple doses. Genetically modified viral vectors, such as those engineered for targeted delivery or enhanced antigen presentation, are also covered.

The book further delves into the specific applications of viral vectors in vaccine development, including their use in veterinary medicine and the development of vaccines against emerging infectious diseases. The

advantages and challenges associated with viral vector vaccines are discussed, along with the commercially available viral vector vaccines and the future potential of this technology.

This book serves as a valuable resource for researchers, scientists, and healthcare professionals working in the field of vaccine development. It provides a comprehensive understanding of viral vector technology and its potential to address the challenges of vaccine design and delivery. By exploring the latest advancements and future prospects, this book aims to contribute to the development of safer, more effective, and more accessible vaccines for a healthier global population. The editors are grateful to everyone who has supported their work and also wish to thank Martin Scrivener and Scrivener Publishing for their support and publication.

Editors

Vivek P. Chavda

Vasso Apostolopoulos

Introduction to Viral Vectors

Anjali P. Bedse^{1*}, Suchita P. Dhamane², Shilpa S. Raut¹, Komal P. Mahajan³
and Kajal P. Baviskar⁴

¹*Department of Pharmaceutics, K K Wagh College of Pharmacy, Nashik,
Maharashtra, India*

²*Department of Pharmaceutics, JSPM's Jayawantrao Sawant College of Pharmacy
& Research, Hadapsar, Pune, Maharashtra, India*

³*Department of Pharmacology, K K Wagh College of Pharmacy, Nashik,
Maharashtra, India*

⁴*Department of Pharmaceutical Chemistry, K K Wagh College of Pharmacy,
Nashik, Maharashtra, India*

Abstract

Viral vector manipulation is the most effective way to transfer genes to modify a specific cell type or tissue. Therapeutic genes can also be expressed through this technique. Many virus species are currently being studied for their ability to introduce genes into cells for transgenic expression, which can be either temporary or permanent. These comprise herpes simplex viruses, baculoviruses, adeno-associated viruses, poxviruses, γ -retroviruses, lentiviruses, and adenoviruses (Ads). The selection of a virus for regular clinical usage depends upon several factors, including transgenic expression effectiveness, production ease, safety, toxicity, and stability. An introduction to the general properties of viral vectors frequently used in gene transfer, as well as their benefits and drawbacks for gene therapy applications, is given in this chapter.

Keywords: Viral vectors, gene transfer, transgene expression, adenoviruses, gene therapy

*Corresponding author: dranjalibedse@gmail.com

Vivek P. Chavda and Vasso Apostolopoulos (eds.) *Viral Vectors for Vaccine Delivery*, (1–24) © 2025
Scrivener Publishing LLC

1.1 Introduction

For decades, traditional vaccination platforms such as live-attenuated or killed viral vaccines have been utilized effectively in inducing long-term immunity to various kinds of pathogenic human diseases. However, for many human infections, such vaccination platforms, especially live-attenuated vaccines, are unsuitable for human usage due to safety issues, low efficacy, or basic impracticality [1].

In a phase 1 clinical trial of a live-attenuated dengue virus vaccine, side effects produced by the vaccine virus strain's under-attenuation were observed [2].

Certain infections, including the Ebola and Marburg viruses belonging to the Filoviridae family, are so deadly that live-attenuated vaccines are not even considered because the risk of the vaccine strain becoming under-attenuated or reverting to a pathogenic state would be too great. The persistent need for developing novel, safer, and more effective vaccine platforms has led researchers to explore alternate approaches for vaccine production, including DNA vaccines, viral-vectored immunizations, and recombinant protein subunit vaccines. One of the most promising platforms for recombinant vaccine research is the viral vector. A viral vector is comparable to a small delivery device that can transport genetic material to the cell nucleus. The viral vector has the genetic material loaded and packaged into it. The purpose of using viral vectors for vaccination is to introduce the target pathogen's naturally existing antigens to the immune system without the infectious pathogen [1].

Viral vectors can be categorized into two main groups based on their genomic behavior within host cells: those that integrate into the host cellular chromatin, such as oncoretroviruses and lentiviruses, and those that primarily exist as extrachromosomal episomes within the cell nucleus, including adeno-associated viruses (AAV), adenoviruses (Ads), and herpesviruses. This classification is crucial for understanding their mechanisms of action and potential applications in gene therapy and vaccination. The selection of viral vectors for clinical use is influenced by several critical factors, including stability, toxicity, safety, ease of manufacturing, and the efficiency of transgene expression. These considerations ensure that the chosen vector is suitable for the intended therapeutic application while minimizing risks to the patient. Viral vectors encompass both RNA and DNA viruses, which can be further divided based on their genomic structure into single-stranded (ss) and double-stranded (ds) genomes. For instance, retroviruses typically possess an ssRNA genome that must be

reverse-transcribed into dsDNA before integration into the host genome. In contrast, Ads are characterized by their dsDNA genomes and are known for their ability to transiently express genes without integrating into the host genome.

The distinct properties of each viral vector type contribute to their effectiveness in various therapeutic contexts. For example, retroviral vectors are particularly effective for stable gene integration in dividing cells, while AAVs are favored for their low immunogenicity and ability to transduce both dividing and nondividing cells. Ads offer high transduction efficiency and large packaging capacity, making them suitable for delivering larger genetic payloads [3, 4].

1.2 Baculovirus Vectors

A safe, nontoxic, non-integrative vector with a high replication capability is the baculovirus. Since baculoviruses may infect both latent and growing cells, they are also a highly versatile, inexpensive vector with a wide tissue and host tropism. Additionally, they are more biosafe since they only reproduce in insect cells—not in mammalian cells. Baculoviruses are a desirable choice for gene transfer due to their advantageous characteristics. Regenerative medicine, anticancer treatments, and vaccine development have all benefited greatly from the substantial advancements made in using baculoviruses in gene therapy. Nowadays, the main applications of baculoviruses are in the manufacture of vaccines and recombinant proteins. New avenues for the production of vaccines of the next generation have been made possible by the stimulation of mucosal and systemic immune responses by baculoviruses through oral or intranasal delivery. This human-friendly virus will undoubtedly be promoted as a viable vector for clinical applications if further knowledge about the biology of baculoviruses and their interactions with non-native hosts is obtained [5, 6].

The term “baculovirus” refers to the unique rod-shaped viral particles produced in infected insect cells, known as occlusion bodies. Baculoviruses are frequently employed in insect cell culture systems as expression vectors. The baculovirus can be modified to include foreign genes in its genome, which allows the virus to infect insect cells. This makes it possible to produce significant quantities of recombinant proteins for scientific or commercial uses.

Baculoviruses have been assessed as potential carriers of antigens to elicit immunological responses, making them attractive candidates for the production of vaccines [5].

1.3 Adenovirus Vectors

Adenoviral vectors (AdVs) have emerged as the most widely used vehicle for gene therapy in cancer treatment. These vectors are also employed in vaccination strategies to deliver foreign antigens and in various gene therapy applications. In many cases, AdVs are engineered to be replication-defective; this involves the deletion of essential viral genes, which are then replaced with a genetic cassette that expresses a therapeutic gene. Such modifications allow for targeted gene delivery while minimizing the risk of viral replication in healthy tissues. In the context of cancer therapy, replication-competent AdVs, known as oncolytic vectors, have been developed. These vectors are specifically designed to replicate within cancer cells, utilizing the natural lytic cycle of the virus to induce cell death selectively. By exploiting the unique vulnerabilities of tumor cells, oncolytic Ads can effectively target and destroy malignant tissues while sparing normal cells.

Numerous clinical trials have demonstrated the safety and therapeutic efficacy of both replication-defective and replication-competent AdVs. For instance, studies have shown that these vectors can elicit robust immune responses against tumors, enhancing their potential as therapeutic agents. The ability of AdVs to infect a broad range of cell types and their capacity to induce strong cellular and humoral immune responses further support their utility in cancer treatment. Moreover, AdVs can be engineered to express immune-modulatory molecules or tumor-specific antigens, which can enhance antitumor immunity. This versatility makes them suitable not only for direct cancer therapies but also for combination strategies with existing treatments such as immune checkpoint inhibitors [7].

Although Ads have been used as gene delivery vehicles since the invention of gene therapy, Ad vaccines, like mRNA vaccines, are a more recent approach [8, 9]. The viral replication genes E1 and/or E3 are removed and substituted for the desired transgene, like an antigen, to form a vector. This prevents the virus from expressing the desired antigen and stops it from replicating its genome after infection. In comparison to mRNA vaccines, Ads have a number of advantages, such as the previously mentioned low cost and thermostability [10].

Ad vector vaccinations generally elicit robust transgenic antigen-specific cellular (specifically, CD8⁺ T cells) and/or humoral immune responses, making them immunogenic vaccines [11].

The potential of AdVs to elicit a potent and well-balanced immune response makes them ideal for use in the COVID-19 pandemic. These vectors have been studied as vaccine agents for a variety of infectious diseases

[12, 13]. Early AdV systems faced biological challenges, but the distinct molecular characteristics of these vectors facilitated the rapid development of vaccines with complex designs [10, 14].

AdVs have the benefit of high infection effectiveness and a significant cargo limit. AdVs have a significant disadvantage in that they are highly cytotoxic; nevertheless, this characteristic can be useful when the vectors are employed as oncolytic viruses. Although there are drawbacks of transient gene expression, safety benefits outweigh them as gene expression on unintentional targets would be transient [14].

AdVs are categorized into first, second, and third generations based on their genetic makeup. First-generation AdVs can only be produced using a packaging cell line that expresses the E1 protein; they are not capable of self-replication. The most widely utilized packaging cells are human embryonic kidney 293 cells.

Most human cells produce E1A-like proteins; therefore, even first-generation AdVs with deleted E1 sections can cause robust host immune responses and persistent cytotoxicity in transduced host cells. Another strategy was to develop a second-generation Ad without E2 and E4 deletions in order to lessen the host cell's immune response to the vector. The E2 section encodes genes related to Ad replication, while the E4 region encodes regulatory proteins related to DNA transcription.

Second-generation Ads continue to elicit host immune responses and reduce transgenic expression in target cells by expressing adenoviral proteins through the remaining genes. The production of third-generation AdVs, often referred to as “helper-dependent vectors,” involves co-introducing a “helper adenovirus”—a virus that carries the genes required for replication—into the packed cells. Third-generation Ads can be contaminated by helper Ads, and self-propagating Ads can result from homologous recombination between helper viruses and packing cells [15].

Gendicine, a recombinant human p53 adenovirus, was approved by the China Food and Drug Administration (CFDA) in 2003 as a first-in-class gene therapy product for head and neck cancer treatment. Gendicine is a biological medication that can be given in three different ways: intravascular infusion, intracavity, or minimally invasive intratumoral injection. The wild-type (wt) p53 protein produced by Gendicine-transduced cells has a tumor-suppressive role in response to cellular stress. It induces apoptosis, senescence, and/or autophagy, depending on the conditions of the cellular stress. It also promotes cell-cycle arrest and DNA repair. Gendicine has demonstrated notably higher response rates when combined with radiation and chemotherapy than when used with traditional therapies alone. Additionally, its safety record is really good. Apart from head and neck

cancer, other cancer types and illness stages have also been effectively treated with metronidazole. No major side effects have been noted, with the exception of 50 to 60% of patients experiencing vector-associated transient fever, which persisted for a few hours [16].

1.4 Poxvirus Vectors

Poxviruses are a large, complex virus belonging to the Poxviridae family that can affect both vertebrates and invertebrates. Poxviruses are comparatively large and oval-shaped viruses. Poxviridae is subdivided into two subfamilies: Chordopoxvirinae (vertebrate poxviruses) and Entomopoxvirinae (insect poxviruses). The subfamily Chordopoxvirinae has been further divided into nine genera, four of which contain viruses that cause diseases in humans (Orthopoxvirus, Parapoxvirus, Molluscipoxvirus, and Yatapoxvirus). Smallpox and molluscum contagiosum are diseases that affect humans, whereas the other two are zoonotic infections. The virion is enclosed, and the genome is protected in a protein sheath. Among all DNA viruses, poxviruses are distinct in that they can only reproduce outside of the nucleus, in the cytoplasm of the host cell. To encode the various enzymes and proteins involved in viral DNA replication and gene transcription, a large genome is therefore required [17].

Poxvirus infections can cause lesions, skin nodules, or a severe rash. Variola virus, the causative agent of smallpox, caused enormous morbidity and mortality in human communities before its effective eradication. The smallpox vaccine, which was essential in the eradication of smallpox, is based on the vaccinia virus (VV), a poxvirus closely related to the variola virus. The vaccination protected against smallpox without developing it. Though smallpox is no longer around, other poxviruses can infect humans. Monkeypox and VVs are two examples. Monkeypox is related to smallpox but produces a less severe sickness in humans. The smallpox vaccine is based on the VV.

Poxviruses have been utilized as vectors for foreign gene expression in mammalian cells. Modified poxviruses, such as modified vaccinia Ankara (MVA), are used as vaccine vectors in the treatment of a variety of infectious diseases. Poxviruses are open to genetic modification because of their enormous genomes. This has been used for various applications, including gene delivery vector application in research and the development of recombinant vaccines [18].

The ability of poxviruses to produce cellular and humoral immunity, their huge genome size with several immunomodulatory genes, and their

tolerance for significant heterologous gene insertions are the major characteristics that make them good antigen delivery platforms and vaccine vectors. Initially, the VV was designed to express heterologous genes. Later, with promising results, the potential of using swinepox, parapoxvirus, and avipoxvirus as vectors was additionally examined. In order to mitigate the safety risks associated with wt poxviruses, a variety of severely attenuated strains with replication defects have been created, primarily by repetitive cycles in cell culture [19].

The thymidine kinase (TK) gene has been specifically targeted for insertional inactivation in the majority of recombinant poxviruses produced too far. This involves introducing a heterologous gene into the TK locus within the poxvirus genome. Poxviridae family recombinant VV vectors proliferate and transcribe their genome in infected cells' cytosol. Thus, it is important that viral DNA is incorporated into the host's genome. VV is the preferred vector for transient gene expression since it infects almost all types of mammalian cells. Its massive, adaptable genome makes it possible to insert large DNA segments up to 25 kb in size. This virus has three distinct stages in its infectious cycle. Genes in the early phase code for enzyme proteins, while genes in the intermediate phase control the expression of genes in the late phase, which codes for structural proteins. Promoting the expression of the inserted gene of interest is possible by means of the 7.5-kDa protein that encodes the promoter gene, which is active during both the early and late phases of infection. The wt VV is cytolytic, while less virulent poxvirus vectors like MVA or fowl pox virus are commonly used for cell transduction.

To create safer and more versatile poxvirus-vectored vaccine candidates, other immunomodulatory genes have also been used recently. In heterologous prime-boost vaccination regimens, in which poxvirus vectors are combined with other killed or DNA vaccine formulations, it has been demonstrated that poxvirus vectors are highly effective. The number of vaccinations based on the poxvirus has been approved for use against various animal infections, such as the canine distemper virus (CDV), rabies virus (RabV), avian influenza virus (AIV), and West Nile virus (WNV) [19].

VV is a member of the poxvirus family. An icosahedral papovavirus is called Simian virus-40(SV40). Recently, alterations have been implemented in Simian virus-40 (SV40) to enable it to serve as a vector for gene delivery. Gene transfer vectors that exhibit certain distinctive characteristics include recombinant SV40 (rSV40) vectors: SV40 is a widely recognized virus, and it is simple to create nonreplicative vectors at titers of 10¹² IU/ml. Additionally, these successfully transduce both dormant and proliferating

cells, are nonimmunogenic, and provide a broad variety of cell types with sustained transgene expression. The limited ability to clone viruses and the potential risks associated with the random integration of the viral genome into the host genome are currently the drawbacks of using rSV40 vectors for gene therapy [20].

1.5 Herpes Virus Vectors

Herpesviruses are well known for being able to cause latent infections. Some cells may experience the virus going dormant after an initial active infection, and subsequent reactivations can result in recurring infections. Many individuals carry herpes viruses without showing any symptoms, and these kinds of viruses are very widespread. Some people, particularly those with compromised immune systems, may experience more severe herpesvirus infections and consequent complications [21].

Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae are the three subfamilies of the nine herpes viruses that are known to infect humans (Figure 1.1).

Herpesviruses with reduced virulence are engineered to carry heterologous immunogens that specifically target a number of hazardous and important infections. These compounds are remarkable for their ability to elicit humoral and cell-mediated immune responses, as well as to accept large amounts of foreign DNA.




Figure 1.1 Structure and types of herpesviruses.

A strong basis for the advancement of herpesvirus-based vectors is established by a better understanding of the interaction between the vector and the host. Currently, a variety of molecular techniques, including codon optimization, homologous and two-step *en passant* mutagenesis, BAC technology, and the CRISPR/Cas9 system, are used to facilitate the generation of herpesvirus-based recombinant vaccine vectors [22].

Herpes simplex virus (HSV) vectors are appropriate for transferring and expressing several large therapeutic genes in brain neurons over an extended period of time, even in the total absence of viral gene expression. The advanced vector technologies are safe, long-lasting, and non-inflammatory within the nucleus of nerve cells. HSV may eventually be utilized to treat a number of neurodegenerative disorders with an identified inherited cause [21].

1.6 Epstein-Barr Virus Vectors

The Epstein-Barr virus (EBV) vector is characterized by its ability to persist in the host cell nucleus as an episome, rather than integrating into the host genome. This property renders it a highly accessible and efficient vector for use in human cell lines. The EBV vector comprises two key DNA components: the nuclear antigen-1 (EBNA1) gene, which is expressed by the virus, and the OriP sequence, which serves as the origin of plasmid replication. The EBNA1 protein plays a crucial role in maintaining the stability of the episome by binding to the OriP sequence. This interaction facilitates the anchoring of OriP-containing plasmids to nuclear proteins within the host cell, allowing them to remain stable episomes during cell division. As a result, these plasmids can replicate alongside the host's cellular machinery without disrupting genomic integrity. The unique characteristics of EBV vectors make them particularly suitable for various applications in gene therapy and vaccine development. Their episomal nature allows for sustained expression of therapeutic genes without the risks associated with genomic integration, such as insertional mutagenesis. This aspect is especially important in therapeutic contexts where long-term gene expression is desired. Furthermore, EBV vectors can be engineered to enhance their functionality. For instance, modifications can be made to improve their replication efficiency or to include additional regulatory elements that enhance transgene expression. This adaptability makes EBV vectors a valuable tool in both research and clinical settings [23].

Research on alpha herpes virus has significantly improved several genetic techniques, and EBV replication is comparable to that of other

herpes viruses. However, EBV is distinct from alpha herpes viruses in that it induces latency in human B cells and modifies their growth [24].

EBV vectors with OriP-containing plasmid replicate once throughout the cell cycle in parallel with the host chromosomes. The high-affinity matrix attachment area containing oriP is responsible for anchoring EBV vectors, which have a chromatin-like structure, to the nuclear matrix in latently infected cells.

The two noncontiguous portions that make up OriP are the dyad symmetry (DS) element and the family of repetitions (FR). A 30-bp repeat sequence is present in 20 tandem flawed copies in the FR and four similar copies in the DS, the other region. The majority of sequences for EBNA1 binding are present in these 30-bp repeats.

With the use of EBV-based vectors, deficient human cell lines can be effectively corrected by cDNA or genomic DNA transfections leading to complementation and cloning of the correcting gene. It is possible to target tumor cells that express EBNA-1 specifically with vectors containing only oriP in EBV-associated neoplasms such as nasopharyngeal carcinoma and Burkitt's lymphoma [25].

1.7 Retrovirus Vectors

Gene therapy commonly uses viruses, specifically retroviruses, as vectors. The genetic material found in retroviruses is RNA. Reverse transcription is the process by which the retrovirus converts RNA into DNA once it enters the host cell. The provirus, which is the viral DNA that has been created, is integrated into the host cell's DNA. Proviruses often provide no risk to users. There is a significant risk, though, as some retroviruses have the ability to turn healthy cells malignant.

Retroviruses must render them harmless prior to using them as a vector. For instance, by deliberately deleting a gene that codes for the viral envelope, the retrovirus can be made inert. A retrovirus cannot enter the host cell if it does not have the envelope. A single envelope-defective retrovirus can multiply into many viral particles with the help of helper viruses. Helper viruses possess the usual genes that produce envelopes. Because the vector virus has a malfunctioning envelope gene, it can multiply together with the helper virus when it infects host cells (Figure 1.2). The vector and helper viruses multiply billions of times by repeatedly replicating in the host cells. It is possible to isolate and purify the vector viruses from the helper viruses. It is crucial to isolate vector viruses and ensure they are




Figure 1.2 Large-scale production of vector viruses using helper viruses.

completely free of helper viruses. The health of patients receiving gene therapy is seriously threatened by helper virus contamination.

A retroviral vector carrying a maximum 8-kb size therapeutic DNA is useful for transforming the cells. However, the integration and delivery efficiency of therapeutic DNA is poor. To achieve high efficiency of integration, packaged retroviral RNA particles are used.

1.8 Lentivirus Vectors

Lentiviruses are among the most popular and useful viral vectors in the laboratory. Lentiviruses have two advantages: they have a large genetic capacity and can transduce both proliferating and nondividing cells. At the beginning of the 1990s, investigators developed viral vector systems based on retroviruses, such as the Moloney murine leukemia virus (MMLV).

Only actively dividing cells were susceptible to infection by the vectors, but they also had the ability to integrate into the genome and support transgenic expression for a long time. While nondividing cells might be infected by a different type of adenovirus-based vector, transgenic expression would not be produced over time. The packaging, envelope, and transfer plasmids constituted the original lentiviral vector system. The HIV-1 provirus mutant included in the packaging plasmid was unable to package itself because it lacked a few necessary proteins. The cell types that the vector could infect were determined by the viral envelope present on

the envelope plasmid. Finally, the necessary transgene and HIV-1 long-terminal repeats (LTRs) were included in the transfer plasmid, helping to facilitate the integration of the virus into the host genome. After these plasmids were co-transfected, 293T cells released transgene-containing lentiviral particles into the medium, which could be collected for use in research. Lentiviral vectors are still widely used for tracing and targeting brain cells because they can carry a significantly larger genetic cargo (8 kb versus 4.5 kb) than adeno-associated viral vectors, even though the latter can also target nondividing cells (Figure 1.3) [26, 27].

Lentiviruses have been studied for decades by researchers. Because it naturally inserts genetic material into cells, especially stem cells, HIV is the most well-known lentivirus. The lentiviral vector is built using an HIV virus blueprint. The HIV virus is made up of nine genes. Researchers take three or four different genes from the HIV virus's blueprint to create the lentiviral vector, which increases the vector's ability to transfer genetic material. Now, more genes will be added in order to produce the desired therapeutic effect. Since only a small portion of the nine genes from the original viral blueprint are used, HIV infection is impossible due to incomplete genomes.




Figure 1.3 HIV genome and lentiviral vector.